NCT00550017 - A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Advanced Solid Tumors

Interventions

DRUG

Epofolate

Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1 through 4 of a 21-day cycle, until the disease progresses

Trial Locations (4)

55905

Mayo Clinic, Rochester

K1H 8L6

Local Institution, Ottawa

M5G 2M9

Local Institution, Toronto

NE7 7DN

Local Institution, Newcastle upon Tyne